Base de dados : MEDLINE
Pesquisa : D02.540.505 [Categoria DeCS]
Referências encontradas : 10971 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1098 ir para página                         

  1 / 10971 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29377957
[Au] Autor:Yang D; Chen L; Chen Z
[Ad] Endereço:Zhejiang University School of Medicine, Hangzhou, Zhejiang, P.R. China.
[Ti] Título:The timing of azithromycin treatment is not associated with the clinical prognosis of childhood Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings.
[So] Source:PLoS One;13(1):e0191951, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Mycoplasma pneumoniae infection is a major cause of community-acquired pneumonia in children. We performed a retrospective study to evaluate the clinical impact of the timing of azithromycin treatment in children with Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings. METHODS AND FINDINGS: A total of 623 patients were enrolled in this study and were divided into 2 groups according to the timing of azithromycin therapy. Children who received azithromycin within 3 days (72 hours) after the onset of Mycoplasma pneumoniae pneumonia were classified into the early azithromycin treatment group (n = 174), whereas the late azithromycin treatment group (n = 449) comprised children treated with azithromycin more than 72 hours after symptom onset. We evaluated clinical prognosis according to demographic, clinical and laboratory characteristics. Although the early azithromycin treatment group exhibited a longer fever duration after azithromycin administration (7.17±4.12 versus 4.82±3.99 days, P<0.01), the total fever duration exhibited no significant difference (9.02±4.58 versus 9.57±4.91 days, P = 0.212). After azithromycin therapy, the two groups exhibited no significant differences with respect to improvements in the laboratory and radiological findings (all P>0.05). CONCLUSION: The timing of azithromycin treatment is not associated with the clinical prognosis of Mycoplasma pneumoniae pneumonia in children in high macrolide-resistant Mycoplasma pneumoniae prevalence settings.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Azitromicina/uso terapêutico
Macrolídeos/uso terapêutico
Pneumonia Bacteriana/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Farmacorresistência Bacteriana
Feminino
Seres Humanos
Lactente
Masculino
Pneumonia Bacteriana/patologia
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Macrolides); 83905-01-5 (Azithromycin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191951


  2 / 10971 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29441912
[Au] Autor:Wu JX; Zhang G; Song M; Liu M; Liang JL; Xu JL; Shang F; Qi P
[Ti] Título:Determination of gamithromycin in an injection by ultra-performance liquid chromatography-tandem quadrupole-time-of-flight mass spectrometry.
[So] Source:Pharmazie;71(7):378-381, 2016 Jul 07.
[Is] ISSN:0031-7144
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:In this study, a sensitive and precise method was developed for the determination of gamithromycin in an injection using ultra-performance liquid chromatography-tandem quadrupole-time-of-flight mass spectrometry (UPLC-QTOF-MS) and the results were compared with a similar analysis for the ion fragments of gamithromycin in MS/ MS. The sample was dissolved in methanol then filtered and separated on a C18 column using acetonitrile-0.1% formic acid (containing 2 mmol/L ammonium acetate) as the mobile phase. The flow rate was 0.4 mL/min and the column temperature was 40 °C. The mass spectrometry conditions were electrospray ionization (ESI) operated in positive ion full scan mode and quantified using external calibration. Subsequently, ion fragments of the MS/MS were compared and analyzed. The linear range was 10 ∼ 200 µg/L with a correlation coefficient of 0.9992. The limit of detection (LOD) was 0.77 µg/L and the limit of quantitation (LOQ) was 2.55 µg/L. The average recoveries of the intra-assay were 98.8%-105.6% with a relative standard deviation ranging from 1.79% to 2.38% and the inter-assay were 89.3%-110.7% with a relative standard deviation ranging from 4.93% to 6.27%. After the comparative analysis of the fragments with a Molecular Structure Correlator, the score of the total matching degree reached 83.19 and the scores of each ion fragment matching degree were all greater than 90, which supplied the basis for the confirmation of gamithromycin. The results indicated that the method was simple, sensitive and precise and could be applied in the determination of gamithromycin in real samples.
[Mh] Termos MeSH primário: Antibacterianos/análise
Macrolídeos/análise
[Mh] Termos MeSH secundário: Cromatografia Líquida de Alta Pressão
Indicadores e Reagentes
Limite de Detecção
Padrões de Referência
Reprodutibilidade dos Testes
Espectrometria de Massas por Ionização por Electrospray
Espectrometria de Massas em Tandem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Indicators and Reagents); 0 (Macrolides); ZE856183S0 (gamithromycin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1691/ph.2016.6004


  3 / 10971 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29223571
[Au] Autor:Perdigão GMC; Lopes MS; Marques LB; Prazeres PHDM; Gomes KS; de Oliveira RB; Pinto MCX; de Souza-Fagundes EM
[Ad] Endereço:Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
[Ti] Título:Novel nitroaromatic compound activates autophagy and apoptosis pathways in HL60 cells.
[So] Source:Chem Biol Interact;283:107-115, 2018 Mar 01.
[Is] ISSN:1872-7786
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:N-(2-butanoyloxyethyl)-4-(chloromethyl)-3-nitrobenzamide (NBCN) is a nitroaromatic bioreducible compound with cytotoxic effects in cancer cell lines. The aim of this work was to investigate the molecular mechanisms involved in cell death promoted by NBCN in HL60 cells. We observed that NBCN treatment increased intracellular ROS and reduced mitochondria membrane potential (ΔΨm). NBCN treatment also induced morphological changes, phosphatidylserine exposure, cell cycle arrest in G2/M-phase, DNA condensation and fragmentation, but it did not show cytotoxic effects on normal human peripheral blood mononuclear cells (PBMCs). NBCN-induced caspase 3- and 9-dependent DNA fragmentation, which was blocked by pretreatment with the broad-spectrum caspase inhibitor, z-VAD-fmk. Flow cytometry analysis demonstrated that NBCN also increased of the number of autophagic vesicles in HL60 cells, which was not observed when cells were pre-treated with bafilomycin A1. Taken together, these results indicate that NBCN triggered the mitochondrial apoptotic pathway and led to the onset of autophagic cell death, which contributed to its cytotoxic effects.
[Mh] Termos MeSH primário: Apoptose/efeitos dos fármacos
Autofagia/efeitos dos fármacos
Benzamidinas/toxicidade
[Mh] Termos MeSH secundário: Clorometilcetonas de Aminoácidos/farmacologia
Benzamidinas/química
Inibidores de Caspase/farmacologia
Caspases/metabolismo
Células Cultivadas
Fragmentação do DNA/efeitos dos fármacos
Pontos de Checagem da Fase G2 do Ciclo Celular/efeitos dos fármacos
Células HL-60
Seres Humanos
Leucócitos Mononucleares/citologia
Leucócitos Mononucleares/efeitos dos fármacos
Leucócitos Mononucleares/metabolismo
Pontos de Checagem da Fase M do Ciclo Celular/efeitos dos fármacos
Macrolídeos/farmacologia
Potencial da Membrana Mitocondrial/efeitos dos fármacos
Espécies Reativas de Oxigênio/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amino Acid Chloromethyl Ketones); 0 (Benzamidines); 0 (Caspase Inhibitors); 0 (Macrolides); 0 (Reactive Oxygen Species); 0 (benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone); 3459-99-2 (3-nitrobenzamidine); 88899-55-2 (bafilomycin A1); EC 3.4.22.- (Caspases)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171211
[St] Status:MEDLINE


  4 / 10971 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29220516
[Au] Autor:Depalo L; Lanzoni A; Masetti A; Pasqualini E; Burgio G
[Ad] Endereço:Dipartimento di Scienze Agrarie-Entomologia, Alma Mater Studiorum-Università di Bologna, Italy.
[Ti] Título:Lethal and Sub-lethal Effects of Four Insecticides on the Aphidophagous Coccinellid Adalia bipunctata (Coleoptera: Coccinellidae).
[So] Source:J Econ Entomol;110(6):2662-2671, 2017 12 05.
[Is] ISSN:1938-291X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Conventional insecticide assays, which measure the effects of insecticide exposure on short-term mortality, overlook important traits, including persistence of toxicity or sub-lethal effects. Therefore, such approaches are especially inadequate for prediction of the overall impact of insecticides on beneficial arthropods. In this study, the side effects of four modern insecticides (chlorantraniliprole, emamectin benzoate, spinosad, and spirotetramat) on Adalia bipunctata (L.) (Coleoptera: Coccinellidae) were evaluated under laboratory conditions by exposition on treated potted plants. In addition to investigation of acute toxicity and persistence of harmful activity in both larvae and adults of A. bipunctata, demographic parameters were evaluated, to provide a comprehensive picture of the nontarget effects of these products. Field doses of the four insecticides caused detrimental effects to A. bipunctata; but in different ways. Overall, spinosad showed the best toxicological profile among the products tested. Emamectin benzoate could be considered a low-risk insecticide, but had high persistence. Chlorantraniliprole exhibited lethal effects on early instar larvae and adults, along with a long-lasting activity, instead spirotetramat showed a low impact on larval and adult mortality and can be considered a short-lived insecticide. However, demographic analysis demonstrated that chlorantraniliprole and spirotetramat caused sub-lethal effects. Our findings highlight that sole assessment of mortality can lead to underestimation of the full impact of pesticides on nontarget insects. Demographic analysis was demonstrated to be a sensitive method for detection of the sub-lethal effects of insecticides on A. bipunctata, and this approach should be considered for evaluation of insecticide selectivity.
[Mh] Termos MeSH primário: Coleópteros/efeitos dos fármacos
Inseticidas/toxicidade
[Mh] Termos MeSH secundário: Animais
Compostos Aza/toxicidade
Coleópteros/crescimento & desenvolvimento
Combinação de Medicamentos
Ivermectina/análogos & derivados
Ivermectina/toxicidade
Larva/efeitos dos fármacos
Larva/crescimento & desenvolvimento
Macrolídeos/toxicidade
Compostos de Espiro/toxicidade
ortoaminobenzoatos/toxicidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Aza Compounds); 0 (Drug Combinations); 0 (Insecticides); 0 (Macrolides); 0 (Spiro Compounds); 0 (ortho-Aminobenzoates); 4G7KR034OX (spirotetramat); 622AK9DH9G (chlorantranilipole); 70288-86-7 (Ivermectin); HVM3G4A01W (emamectin benzoate); XPA88EAP6V (spinosad)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE
[do] DOI:10.1093/jee/tox243


  5 / 10971 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29268637
[Au] Autor:Melani AS; Lanzarone N; Rottoli P
[Ad] Endereço:a Fisiopatologia e Riabilitazione Respiratoria, Dipartimento Vasi, Cuore e Torace, Policlinico Le Scotte , Azienda Ospedaliera Universitaria Senese , Siena , Italy.
[Ti] Título:The pharmacological treatment of bronchiectasis.
[So] Source:Expert Rev Clin Pharmacol;11(3):245-258, 2018 Mar.
[Is] ISSN:1751-2441
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Until recently considered as a minor health problem, the role of bronchiectasis is now increasingly recognized. New specific drugs are being approved for treatment of bronchiectasis. Possibly they will offer better perspectives to bronchiectatic subjects with evolving course. Areas covered: We provide an overview of aetiopathogenesis, clinics and non-pharmacological management, extending the topic of pharmacological treatment. Present therapies were extrapolated from other chronic lung diseases, but newer promising specific drugs are being awaited. Therapy aims at improving mobilisation of bronchial secretions and, if any, reversing airflow obstruction. Antibiotics are indicated to treat exacerbations, eradicate or reduce sputum bacterial load. Expert commentary: Over the last years evidence is mounted that bronchiectatic subjects with accelerated course of disease should be referred to secondary and tertiary centres. This requires increased awareness on the role and the frequency of bronchiectasis in primary care. Long-term continuous or cyclical use of antibiotics is recommended to stabilize or improve the course of evolving disease. Macrolides are a currently preferred option. Inhaled antibiotics are gaining importance and are the object of ongoing research interest. Practical challenges of inhaled antibiotic treatment remain the need of defining the best therapeutic regimen and optimizing true adherence.
[Mh] Termos MeSH primário: Antibacterianos/administração & dosagem
Bronquiectasia/tratamento farmacológico
Desenho de Drogas
[Mh] Termos MeSH secundário: Administração por Inalação
Obstrução das Vias Respiratórias/tratamento farmacológico
Obstrução das Vias Respiratórias/etiologia
Bronquiectasia/microbiologia
Bronquiectasia/patologia
Seres Humanos
Macrolídeos/administração & dosagem
Adesão à Medicação
Escarro
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Macrolides)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171223
[St] Status:MEDLINE
[do] DOI:10.1080/17512433.2018.1421064


  6 / 10971 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29386433
[Au] Autor:Hatakeyama S
[Ad] Endereço:Graduate School of Biomedical Sciences, Nagasaki University.
[Ti] Título:[Stereocontrolled Total Synthesis of Biologically Active Natural Products].
[So] Source:Yakugaku Zasshi;138(2):191-209, 2018.
[Is] ISSN:1347-5231
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo: This review article describes the total syntheses of englerin A, ophiodilactones A and B, marinomycin A, N-methylwelwitindolinone C isothiocyanate, tirandamycins A-D, and tirandalydigin, which possess intriguing biological activities and challenging structures with characteristic ring systems. The focus is on the synthetic methodologies that lead to the highly stereocontrolled assembly of these natural products.
[Mh] Termos MeSH primário: Produtos Biológicos/síntese química
[Mh] Termos MeSH secundário: Alcenos/síntese química
Alcenos/química
Aminoglicosídeos/síntese química
Aminoglicosídeos/química
Derivados de Benzeno/síntese química
Derivados de Benzeno/química
Produtos Biológicos/química
Alcaloides de Indol/síntese química
Alcaloides de Indol/química
Lactonas/síntese química
Lactonas/química
Macrolídeos/síntese química
Macrolídeos/química
Conformação Molecular
Sesquiterpenos de Guaiano/síntese química
Sesquiterpenos de Guaiano/química
Estereoisomerismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Alkenes); 0 (Aminoglycosides); 0 (Benzene Derivatives); 0 (Biological Products); 0 (Indole Alkaloids); 0 (Lactones); 0 (Macrolides); 0 (N-methylwelwitindolinone B isothiocyanate); 0 (Sesquiterpenes, Guaiane); 0 (englerin A); 0 (marinomycin A); 0 (ophiodilactone A); 0 (ophiodilactone B); 0 (tirandamycin C); 0 (tirandamycin D); 114118-91-1 (tirandalydigin); 34429-70-4 (tirandamycin A); 60587-14-6 (tirandamycin B)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1248/yakushi.17-00187


  7 / 10971 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29260224
[Au] Autor:Gerber JS; Ross RK; Bryan M; Localio AR; Szymczak JE; Wasserman R; Barkman D; Odeniyi F; Conaboy K; Bell L; Zaoutis TE; Fiks AG
[Ad] Endereço:Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
[Ti] Título:Association of Broad- vs Narrow-Spectrum Antibiotics With Treatment Failure, Adverse Events, and Quality of Life in Children With Acute Respiratory Tract Infections.
[So] Source:JAMA;318(23):2325-2336, 2017 12 19.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Acute respiratory tract infections account for the majority of antibiotic exposure in children, and broad-spectrum antibiotic prescribing for acute respiratory tract infections is increasing. It is not clear whether broad-spectrum treatment is associated with improved outcomes compared with narrow-spectrum treatment. Objective: To compare the effectiveness of broad-spectrum and narrow-spectrum antibiotic treatment for acute respiratory tract infections in children. Design, Setting, and Participants: A retrospective cohort study assessing clinical outcomes and a prospective cohort study assessing patient-centered outcomes of children between the ages of 6 months and 12 years diagnosed with an acute respiratory tract infection and prescribed an oral antibiotic between January 2015 and April 2016 in a network of 31 pediatric primary care practices in Pennsylvania and New Jersey. Stratified and propensity score-matched analyses to account for confounding by clinician and by patient-level characteristics, respectively, were implemented for both cohorts. Exposures: Broad-spectrum antibiotics vs narrow-spectrum antibiotics. Main Outcomes and Measures: In the retrospective cohort, the primary outcomes were treatment failure and adverse events 14 days after diagnosis. In the prospective cohort, the primary outcomes were quality of life, other patient-centered outcomes, and patient-reported adverse events. Results: Of 30 159 children in the retrospective cohort (19 179 with acute otitis media; 6746, group A streptococcal pharyngitis; and 4234, acute sinusitis), 4307 (14%) were prescribed broad-spectrum antibiotics including amoxicillin-clavulanate, cephalosporins, and macrolides. Broad-spectrum treatment was not associated with a lower rate of treatment failure (3.4% for broad-spectrum antibiotics vs 3.1% for narrow-spectrum antibiotics; risk difference for full matched analysis, 0.3% [95% CI, -0.4% to 0.9%]). Of 2472 children enrolled in the prospective cohort (1100 with acute otitis media; 705, group A streptococcal pharyngitis; and 667, acute sinusitis), 868 (35%) were prescribed broad-spectrum antibiotics. Broad-spectrum antibiotics were associated with a slightly worse child quality of life (score of 90.2 for broad-spectrum antibiotics vs 91.5 for narrow-spectrum antibiotics; score difference for full matched analysis, -1.4% [95% CI, -2.4% to -0.4%]) but not with other patient-centered outcomes. Broad-spectrum treatment was associated with a higher risk of adverse events documented by the clinician (3.7% for broad-spectrum antibiotics vs 2.7% for narrow-spectrum antibiotics; risk difference for full matched analysis, 1.1% [95% CI, 0.4% to 1.8%]) and reported by the patient (35.6% for broad-spectrum antibiotics vs 25.1% for narrow-spectrum antibiotics; risk difference for full matched analysis, 12.2% [95% CI, 7.3% to 17.2%]). Conclusions and Relevance: Among children with acute respiratory tract infections, broad-spectrum antibiotics were not associated with better clinical or patient-centered outcomes compared with narrow-spectrum antibiotics, and were associated with higher rates of adverse events. These data support the use of narrow-spectrum antibiotics for most children with acute respiratory tract infections.
[Mh] Termos MeSH primário: Antibacterianos/efeitos adversos
Otite Média/tratamento farmacológico
Qualidade de Vida
Infecções Respiratórias/tratamento farmacológico
[Mh] Termos MeSH secundário: Doença Aguda
Combinação Amoxicilina e Clavulanato de Potássio/efeitos adversos
Combinação Amoxicilina e Clavulanato de Potássio/uso terapêutico
Antibacterianos/uso terapêutico
Cefalosporinas/efeitos adversos
Cefalosporinas/uso terapêutico
Criança
Pré-Escolar
Feminino
Seres Humanos
Macrolídeos/efeitos adversos
Macrolídeos/uso terapêutico
Masculino
Faringite/tratamento farmacológico
Atenção Primária à Saúde
Estudos Retrospectivos
Sinusite/tratamento farmacológico
Infecções Estreptocócicas/tratamento farmacológico
Streptococcus pyogenes
Falha de Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Cephalosporins); 0 (Macrolides); 74469-00-4 (Amoxicillin-Potassium Clavulanate Combination)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.18715


  8 / 10971 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29317655
[Au] Autor:Pawlowski AC; Stogios PJ; Koteva K; Skarina T; Evdokimova E; Savchenko A; Wright GD
[Ad] Endereço:Michael G. DeGroote Institute for Infectious Disease Research and the Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, L8S 4L8, ON, Canada.
[Ti] Título:The evolution of substrate discrimination in macrolide antibiotic resistance enzymes.
[So] Source:Nat Commun;9(1):112, 2018 01 09.
[Is] ISSN:2041-1723
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The production of antibiotics by microbes in the environment and their use in medicine and agriculture select for existing and emerging resistance. To address this inevitability, prudent development of antibiotic drugs requires careful consideration of resistance evolution. Here, we identify the molecular basis for expanded substrate specificity in MphI, a macrolide kinase (Mph) that does not confer resistance to erythromycin, in contrast to other known Mphs. Using a combination of phylogenetics, drug-resistance phenotypes, and in vitro enzyme assays, we find that MphI and MphK phosphorylate erythromycin poorly resulting in an antibiotic-sensitive phenotype. Using likelihood reconstruction of ancestral sequences and site-saturation combinatorial mutagenesis, supported by Mph crystal structures, we determine that two non-obvious mutations in combination expand the substrate range. This approach should be applicable for studying the functional evolution of any antibiotic resistance enzyme and for evaluating the evolvability of resistance enzymes to new generations of antibiotic scaffolds.
[Mh] Termos MeSH primário: Proteínas de Bactérias/metabolismo
Farmacorresistência Bacteriana
Macrolídeos/metabolismo
Fosfotransferases/metabolismo
[Mh] Termos MeSH secundário: Antibacterianos/química
Antibacterianos/metabolismo
Antibacterianos/farmacologia
Proteínas de Bactérias/química
Proteínas de Bactérias/genética
Eritromicina/química
Eritromicina/metabolismo
Eritromicina/farmacologia
Escherichia coli/efeitos dos fármacos
Escherichia coli/genética
Macrolídeos/química
Macrolídeos/farmacologia
Modelos Moleculares
Estrutura Molecular
Fosfotransferases/classificação
Fosfotransferases/genética
Filogenia
Domínios Proteicos
Especificidade por Substrato
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bacterial Proteins); 0 (Macrolides); 63937KV33D (Erythromycin); EC 2.7.- (Phosphotransferases)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE
[do] DOI:10.1038/s41467-017-02680-0


  9 / 10971 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29199310
[Au] Autor:Thorat RG; Harned AM
[Ad] Endereço:Texas Tech University, Department of Chemistry & Biochemistry, 1204 Boston Ave., Lubbock, TX 79409-1061, USA. andrew.harned@ttu.edu.
[Ti] Título:Rapid, enantioselective synthesis of the C1-C13 fragment of biselyngbyolide B.
[So] Source:Chem Commun (Camb);54(3):241-243, 2018 Jan 02.
[Is] ISSN:1364-548X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A rapid synthesis of the C1-C13 fragment of biselynbyolide A and B is reported. The judicious use of catalytic transformations for C-C bond formation and stereocenter generation greatly minimizes the use of protecting groups and oxidation state changes, as compared to previously reported routes to similar fragments.
[Mh] Termos MeSH primário: Ácidos Graxos Insaturados/síntese química
Macrolídeos/química
[Mh] Termos MeSH secundário: Ácidos Graxos Insaturados/química
Estrutura Molecular
Estereoisomerismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Fatty Acids, Unsaturated); 0 (Macrolides); 0 (biselyngbyolide B)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171205
[St] Status:MEDLINE
[do] DOI:10.1039/c7cc08004b


  10 / 10971 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29241059
[Au] Autor:Del Bianchi A Cruz M; Fernandes MAM; de C Braga PA; Monteiro ALG; Daniel D; Reyes FGR
[Ad] Endereço:Department of Food Science, School of Food Engineering, University of Campinas - UNICAMP, Rua Monteiro Lobato, 80, 13083-862, Campinas, SP, Brazil.
[Ti] Título:Moxidectin residues in lamb tissues: Development and validation of analytical method by UHPLC-MS/MS.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;1072:390-396, 2018 Jan 01.
[Is] ISSN:1873-376X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The development and validation of a throughput method for the quantitation of moxidectin residues in lamb target tissues (muscle, kidney, liver and fat) was conducted using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). To achieve higher recovery of the analyte from the matrices, a modified QuEChERS method was used for sample preparation. The chromatographic separation was achieved using a Zorbax Eclipse Plus C18 RRHD column with a mobile phase comprising 5mM ammonium formate solution +0.1% formic acid (A) and acetonitrile +0.1% formic acid (B) in a linear gradient program. Method validation was performed based on the Commission Decision 2002/657/EC and VICH GL49. To quantify the analyte, matrix-matched analytical curves were constructed with spiked blank tissues, with a limit of quantitation of 5ngg and limit of detection of 1.5ngg for all matrices. The linearity, decision limit, detection capability accuracy, and inter- and intra-day repeatability of the method are reported. The method was successfully applied to incurred lamb tissue samples (muscle, liver, kidney and fat) in a concentration range from 5 to 200µgkg , which demonstrated its suitability for monitoring moxidectin residues in lamb tissues in health surveillance programs, as well as for pharmacokinetics and residue depletion studies.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão/métodos
Resíduos de Drogas/análise
Macrolídeos/análise
Espectrometria de Massas em Tandem/métodos
[Mh] Termos MeSH secundário: Animais
Resíduos de Drogas/química
Resíduos de Drogas/farmacocinética
Rim/química
Rim/metabolismo
Limite de Detecção
Modelos Lineares
Macrolídeos/química
Macrolídeos/farmacocinética
Carne/análise
Músculo Esquelético/química
Músculo Esquelético/metabolismo
Reprodutibilidade dos Testes
Ovinos
Distribuição Tecidual
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Macrolides); 51570-36-6 (milbemycin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171215
[St] Status:MEDLINE



página 1 de 1098 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde